Montelukast Aurobindo Pharma (Malta) (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor type 1 (CysLT1) on cells in the respiratory tract. By preventing leukotriene D4 from binding, it stops the cascade that causes bronchoconstriction, mucus production, vascular leakage and recruitment of inflammatory cells, thereby easing airway narrowing and inflammation.

The exact dose of Montelukast is determined by the prescribing healthcare professional based on the patient’s age, condition and clinical response. Standard dosing guidelines exist, but the prescriber tailors the regimen to each individual and provides specific instructions.

Safety data for Montelukast during pregnancy are limited, and the medication is not classified as safe or unsafe. It should only be used if the potential benefit justifies any possible risk to the fetus. Information on use while breastfeeding is also insufficient; a risk‑benefit assessment should be performed by the clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Montelukast Aurobindo Pharma (Malta). GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists for asthma control. Compared with other leukotriene antagonists such as zafirlukast, Montelukast has a once‑daily dosing schedule and a broader approval for allergic rhinitis, but efficacy is generally comparable across the class.

Montelukast tablets should be stored at room temperature, below 25 °C, in the original packaging. Keep them away from excess moisture, direct sunlight and heat sources. Do not store in the bathroom or near a kitchen sink where humidity is high.

Montelukast is supplied as an oral tablet that should be swallowed whole with a glass of water. It is taken once daily, preferably in the evening, unless the prescriber advises a different schedule. The tablet should not be crushed, chewed or split unless specifically instructed.

Serious adverse reactions include neuropsychiatric events such as agitation, depression, suicidal thoughts, and rare allergic reactions that may present as rash, swelling or anaphylaxis. Liver enzyme elevations have also been reported. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast should be avoided in individuals with a known hypersensitivity to the drug or any of its excipients. It is also not recommended for patients who cannot safely swallow tablets without appropriate medical guidance. The prescriber should evaluate each patient’s medical history before initiating therapy.